Background {#Sec1}
==========

Tumour-related mechanisms define the host immune functions in the tumour microenvironment and decrease the efficiency of the anti-tumour immune competence. This phenomenon plays a key role in the process of hepatocarcinogenesis, where tumour infiltration with immune competent cells exerts a strong influence on prognosis \[[@CR1]\]. In liver cancer, tumour-associated macrophages (TAMs) and monocyte subsets with distinguished functional polarization have a significant impact on cancer-related inflammation and foster tumour escape mechanisms and progression \[[@CR2]\]. These subpopulations of immunologic phenotypes are related to as classically (M1) or alternatively activated (M2) monocytes/macrophages. These monocytes/macrophages deploy their immunoregulatory activities in close interplay with T cell-dependent responses \[[@CR2]\].

Tumour-infiltrating lymphocytes (TILs) play a major role in the progression of solid malignancies and can have a strong influence on the success of the related anti-cancer therapies. TILs in hepatocellular carcinoma (HCC) are mainly T cells. TILs are the hallmark of the anti-cancer immunity in human cancer, on grounds of their ability to specifically interact with and neutralize tumour-related neoantigens \[[@CR3]\]. TILs' immune activity may influence hepatocarcinogenesis not only by direct effects on the adaptive immune system and cytokine interactions, but also further by modulating neoangiogenesis and innate immune responses, i.e. related monocyte/macrophages functions \[[@CR4]--[@CR8]\]. Therefore, the quantification of TILs in solid tumours might help to deliver novel insights concerning their role in the process of hepatocarcinogenesis and to monitor the therapy outcome with immunologic checkpoint inhibition.

Major progress in the efficacy of adjuvant therapies for hepatic malignancies has emerged. However, the restraints of these neoadjuvant regimens constitute an important clinical problem \[[@CR9]\]. Therefore, an additional immune checkpoint blockade represents an attractive therapeutic concept that complements these current therapies in cancer. Furthermore, the pre- and on-treatment quantification of the immunologic infiltrates could deliver novel biomarkers for state of the art disease management, based on the fact that immunological checkpoint targeting is effective only in a scarce amount of the tumour patients \[[@CR10]\]. HCC can arise de novo in non-cirrhotic hepatic environment in approximately 20% of all cases \[[@CR11]\]. However, this subgroup of patients usually presents at an advanced stage of hepatocarcinogenesis, due to the lack of symptoms and surveillance. Therefore, our study aimed to assess the presence and abundance of tumour-infiltrating subsets of monocytes/macrophages and TILs in advanced de novo HCC in non-cirrhosis. This study investigated also their association with tumour recurrence, patient survival and outcome.

Methods {#Sec2}
=======

Patients and tumour specimens {#Sec3}
-----------------------------

Our retrospective study was conducted in 58 patients with de novo HCC in non-cirrhosis. In all patients, a major liver resection with curative intent was performed. None of the included patients had history of viral hepatitis or were treated with neoadjuvant radio- and/or chemotherapy before the tumour resection. Formalin-fixed and paraffin-embedded surgical specimens, embedding a representative tumour sample for immunohistochemical staining, were obtained from the archives of the Department of Pathology. The study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Leipzig University.

Immunohistology {#Sec4}
---------------

The protocols for immunohistology and quantification of positive staining have been published previously \[[@CR12]--[@CR16]\]. The abundance of infiltrating TILs, CD68^+^ and CD163^+^ TAMs were measured in regard to the tumour central area (TCA) and the tumour-infiltrating front (TIF). Zeiss Axio Imager A1 Phase Contrast microscope (Carl Zeiss, Jena, Germany) was used to asses positive staining. Table [1](#Tab1){ref-type="table"} summarizes the antibodies and reagents used to conduct immunohistology.Table 1Antibodies and reagents used for immunostainingAntigenm/pCloneSpeciesCompanySecondary antibodyCompanySubstrateAntigen retrievalCD68mPG-M1MouseAgilentanti-mouse-Ig/ peroxidaseVectorDABTris/EDTA pH 9.0CD163m10D6MouseLeica Biosystems, Newcastle Upon Tyne, UKanti-mouse-Ig/ peroxidaseVectorDAB10 mM citrate, pH 5.5*DAB* 3,3′-diaminobenzidine, *m* monoclonal, *p* polyclonal, *TAM* tumor-associated macrophage

Density quantification of cellular infiltrates {#Sec5}
----------------------------------------------

Quantification was performed as described \[[@CR13]\]. In brief, tumour-infiltrating immune cells were categorized as negative/absent in up to 5% positive cells (0--5% positive cells, score 0) and positive/present (\> 5% positive cells, score 1). HCC patients were then assigned to two groups either to be negative or positive for CD68^+^ or CD163^+^ TAMs. Evaluation of TILs was performed using routine H&E slides as described \[[@CR17]\]. Briefly, the extent of lymphocyte abundance in the tumour area was categorized as none (score 0), low (score 1), moderate (score 2) or high (score 3). Accordingly, HCC patients were then assigned to the TIL^−^ (none to low infiltration) or TIL^+^ group (moderate to high infiltration).

Statistical analysis {#Sec6}
--------------------

The IBM SPSS statistics software was used to perform survival and univariate analysis and to produce the Kaplan-Meier curves (Version 25/Year 2017/USA). The log-rank test was applied to compare differences in survival distributions. The Cox proportional hazards model was utilized to conduct multivariate analysis for the significant parameters in the univariate analysis. The chi-square test, Fisher's exact test or Student's *t* test (independent sample) were applied to compare categorical and continuous variables. Statistical differences were considered significant for *p* ≤ 0.05.

Results {#Sec7}
=======

Table [2](#Tab2){ref-type="table"} summarizes the clinicopathological characteristics of all patients included in the current work. The studied population of HCC patients had 1-, 3- and 5-year survival of 76.4%, 64.1% and 62.2%, respectively. The recurrence-free survival rates 1-, 3- and 5- year after tumour resection were 63.5%, 57.7% and 53.6%, respectively. In 23/58 (39.7%) patients, a recurrent tumour disease was detected and 17/58 (29.3%) patients developed a local tumour recurrence. A metastatic disease was seen in 11/58 (19.0%) patients.Table 2Clinicopathological characteristics of the patients included in the studyVariableValue (%)No. of patients58Gender Female13 (22.4%) Male45 (77.6%)Patient age (years) ≤ 6021 (36.2%) \> 6037 (63.8%)Pathologic T stage T1/T229 (50.0%) T3/T429 (50.0%)Pathologic N stage Positive11 (19.0%) Negative47 (81.0%)Lymphangiosis carcinomatosa Positive17 (29.3%) Negative41 (70.7%)Angioinvasion Positive30 (51.7%) Negative28 (48.3%)Multiple tumour nodules With13 (22.4%) Without45 (77.6%)Tumor size (mm) ≤ 5011 (19.0%) \> 5047 (81.0%)Pathologic R category R049 (84.5%) R1/R29 (15.5%)Histologic differentiation Well11 (19.0%) Moderate/poor47 (81.0%)Distant metastases With11 (19.0%) Without47 (81.0%)Tumor recurrence With23 (39.7%) Without35 (60.3%)Local recurrence With17 (29.3%) Without41 (70.7%)

Distribution of monocytes/macrophages and tumour-infiltrating lymphocytes in HCC {#Sec8}
--------------------------------------------------------------------------------

Figure [1](#Fig1){ref-type="fig"} provides characteristic images for the abundance of TILs and CD68^+^ or CD163^+^ TAMs in HCC. Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} summarize the respective statistical data of the patients. TILs and CD68^+^ or CD163^+^ TAMs revealed a homogeneous expression pattern in TCA and TIF and were also detected in areas of HCC necrosis (Fig. [1](#Fig1){ref-type="fig"}a--f).Fig. 1Immunohistology of monocytes/macrophages and H&E staining of TILs in tumour central area (TCA) of HCC specimens. **a** High density of CD68^+^ TAMs. **b** Low density of CD68^+^ TAMs. **c** High density of CD163^+^ TAMs. **d** Low density of CD163^+^ TAMs. **e** High density of TILs. **f** Low density of TILs. Legend: left column, high density; right column, low density. Black arrows indicate monocytes/macrophages, white arrows TILsTable 3Correlation of CD68^+^ TAMs at the tumour-infiltrating front (TIF) with clinicopathological characteristics in HCCVariableCD68^+^/TIFCD68^−^/TIF*p* valueNo. of patients535Patient age, years0.324 ≤ 6033 (62.3%)4 (80.0%) \> 6020 (37.7%)1 (20.0%)Gender0.430 Female42 (79.2%)3 (60.0%) Male11 (20.8%)2 (40.0%)Local tumour recurrence0.583 Positive15 (28.3%)2 (40.0%) Negative38 (71.7%)3 (60.0%)Overall tumour recurrence0.050 Positive19 (35.8%)4 (80.0%) Negative34 (64.2%)1 (20.0%)Distant Metastases0.209 Positive9 (17.0%)2 (40.0%) Negative44 (83.0%)3 (60.0%)Multiple tumour nodules0.035 Positive10 (18.9%)2 (40.0%) Negative43 (81.1%)3 (60.0%)Tumour size (mm)0.951 ≤ 5010 (10.0%)1 (20.0%) \> 5043 (90.0%)4 (80.0%)R status0.772 Positive8 (15.1%)1 (20.0%) Negative45 (84.9%)4 (80.0%)Angioinvasion0.583 Positive25 (47.2%)2 (40.0%) Negative28 (52.8%)3 (60.0%)Lymphangiosis carcinomatosa0.583 Positive15 (28.3%)2 (40.0%) Negative38 (71.8%)3 (60.0%)Histologic differentiation0.951 Well10 (10.0%)1 (20.0%) Moderate/poor43 (90.0%)4 (80.0%)Pathologic T stage0.148 T1/T228 (53.8%)1 (20.0%) T3/T424 (46.2%)4 (80.0%)Pathologic N stage0.658 Positive2 (03.8%)0 (00.0%) Negative51 (96.2%)5 (100.0%)Table 4Correlation CD163^+^ TAMs in the tumour central area (TCA) or tumour-infiltrating front (TIF) with clinicopathological characteristics in HCCVariableCD163^+^/TCACD163^−^/TCA*p* valueNo. of patients4216Patient age, years0.177 ≤ 6013 (31.0%)8 (50.0%) \> 6029 (69.9%)8 (50.0%)Gender0.680 Female10 (76.2%)3 (18.8%) Male32 (23.8%)13 (81.2%)Local tumour recurrence0.398 Positive11 (26.2%)6 (37.5%) Negative31 (73.8%)10 (62.5%)Overall tumour recurrence0.320 Positive15 (35.7%)8 (50.0%) Negative27 (64.3%)8 (50.0%)Distant metastases0.469 Positive7 (16.7%)4 (25.0%) Negative35 (83.3%)12 (75.0%)Multiple tumour nodules0.016 Positive36 (85.7%)9 (56.3%) Negative6 (14.3%)7 (43.8%)Tumour size (mm)0.438 ≤ 509 (21.4%)2 (12.5%) \> 5033 (78.6%)14 (87.5%)R status0.695 Positive35 (15.1%)2 (12.5%) Negative7 (84.9%)14 (87.5%)Angioinvasion0.311 Positive20 (47.6%)10 (62.5%) Negative22 (52.4%)6 (37.5%)Lymphangiosis carcinomatosa0.656 Positive13 (31.0%)4 (25.0%) Negative29 (69.0%)12 (75.0%)Histologic differentiation0.979 Well8 (19.0%)3 (18.8%) Moderate/poor34 (81.0%)13 (81.3%)Pathologic T stage0.501 T1/T222 (53.7%)7 (43.8%) T3/T419 (46.3%)9 (56.3%)Pathologic N stage0.470 Positive1 (02.4%)1 (06.3%) Negative41 (97.6%)15 (93.7%)No. of patients1939Lymphangiosis carcinomatosa0.035 Positive9 (47.4%)8 (20.5%) Negative10 (52.6%)31 (79.5%)Table 5Correlation of TILs in the tumour central area (TCA) with clinicopathological characteristics in HCCVariableTIL^+^/TCATIL^−^/TCA*p* valueNo. of patients2038Patient age, years0.476 ≤ 606 (30.0%)15 (39.1%) \> 6014 (70.0%)23 (60.9%)Gender0.732 Female15 (75.0%)30 (78.9%) Male5 (25.0%)8 (21.1%)Local tumour recurrence0.933 Positive6 (30.0%)11 (28.9%) Negative14 (70.0%)27 (71.1%)Overall tumour recurrence0.546 Positive9 (45.0%)14 (36.8%) Negative11 (55.0%)24 (63.2%)Metastases0.884 Positive4 (20.0%)7 (18.4%) Negative16 (80.0%)31 (81.6%)Multiple tumour nodules0.100 Positive18 (90.0%)27 (71.1%) Negative2 (10.0%)11 (28.9%)Tumour size (mm)0.206 ≤ 502 (10.0%)9 (23.7%) \> 5018 (90.0%)29 (76.3%)R status0.148 Positive15 (75.0%)34 (89.5%) Negative5 (25.0%)4 (10.5%)Angioinvasion0.717 Positive11 (55.0%)19 (50.0%) Negative9 (45.0%)19 (50.0%)Lymphangiosis carcinomatosa0.057 Positive9 (45.0%)30 (78.9%) Negative11 (45.0%)8 (21.1%)Histologic differentiation0.576 Well3 (15.0%)8 (21.1%) Moderate/poor17 (85.0%)30 (78.9%)Pathologic T stage0.708 T1/T29 (47.4%)20 (52.6%) T3/T410 (52.6%)18 (47.4%)Pathologic N stage0.296 Positive0 (00.0%)2 (5.3%) Negative20 (100.0%)36 (94.7%)CD68^+^ TAMs/TCA0.008 Positive20 (100.0%)11 (28.9%) Negative0 (00.0%)27 (71.1%)

Monocytes/macrophages are associated with reduced incidence of tumour recurrence and formation of multiple tumour nodules in HCC patients {#Sec9}
-----------------------------------------------------------------------------------------------------------------------------------------

CD68^+^ TAMs in TIF were associated with reduced occurrence of recurrent HCC. In the CD68^+^ group, only 19/53 (35.8%) patients suffered overall tumour recurrence, whereas in the CD68^−^ group, 4/5 (80.0%) patients had recurrent disease (*p* = 0.05; Table [3](#Tab3){ref-type="table"}). CD68^+^ TAMs in TIF were also correlated with reduced formation of multiple tumour nodules (*p* = 0.035). In the CD68^+^ group, only 10/53 (18.9%) patients showed this feature, whereas in the CD68^−^ group, these were 2/5 (40.0%) patients (*p* = 0.035).

M2-polarized macrophages are associated with lymphangiosis carcinomatosa and formation of multiple tumour nodules in HCC patients {#Sec10}
---------------------------------------------------------------------------------------------------------------------------------

CD163^+^ TAMs in TCA were associated with the formation of multiple tumour nodules (*p* = 0.016; Table [4](#Tab4){ref-type="table"}). In the CD163^+^ group, 36/42 (85.7%) patients had multiple tumour nodules; in the CD163^−^ group in 9/16 (56.3%) patients, this was diagnosed (*p* = 0.016). Moreover, when considering the TIF, in the CD163^−^ group, 31/39 (79.5%) patients had absence of lymphangiosis carcinomatosa. In the CD163^+^ group, these were 10/19 (52.6%) patients (*p* = 0.035). No significant association between CD163^+^ TAMs in TCA or TIF with CD68^+^ TAMs could be detected.

Tumour-infiltrating lymphocytes are associated with intratumoural monocytes/macrophages in HCC patients {#Sec11}
-------------------------------------------------------------------------------------------------------

TILs in TCA or TIF were not correlated with clinicopathological features of HCC patients (Table [5](#Tab5){ref-type="table"}). However, in regard to the TCA, TILs and CD68^+^ TAMs revealed a strong correlation. In the TIL^+^ group in 20/20 (100%) and in the TIL^−^ group in only 11/38 (28.9%) patients, high frequencies of CD68^+^ TAMs were detected (*p* = 0.008). No significant correlations between TILs in TCA or TIF with CD163^+^ TAMs could be observed.

Influence of monocytes/macrophages and tumour-infiltrating lymphocytes on survival in HCC patients {#Sec12}
--------------------------------------------------------------------------------------------------

In our study, CD68^+^ TAMs and TILs were associated with patients' recurrence-free survival. Figure [2](#Fig2){ref-type="fig"} shows the Kaplan-Meier survival curves. Tables 2, 3, 4 and 5 show the statistical evaluation of all patients. Recurrence-free survival rates were significantly improved in patients with TILs in TCA (Fig. [2](#Fig2){ref-type="fig"}a). One, 3 and 5 years after surgery, these were 68.9%, 63.9% and 61.6%, respectively. Conversely, the survival was 37.8%, 23.4% and 23.4% at 1, 3 and 5 years post-surgery, respectively, in patients without TILs in TCA (*p* = 0.05). Similar data was obtained in regard to CD68^+^ TAMs in TIF (Fig. [2](#Fig2){ref-type="fig"}b). The recurrence-free survival rates were 66.9%, 63.3% and 60.0% at 1, 3 and 5 years for patients with CD68^+^ TAMs in TIF. Contrarily, the recurrence-free survival was 28.7% at 1 year post-surgery in HCC patients without these cells in the TIF. Of note, survival beyond 3 years after surgery could not be reached in patients without CD68^+^ TAMs in TIF (*p* = 0.04). CD163^+^ TAMs in TCA or TIF did not reveal any significant correlation with overall or recurrence-free survival of the HCC patients (CD163^+^ TAMs in TCA: overall survival *p* = 0.858, recurrence-free survival *p* = 0.283; CD163^+^ TAMs in TIF: overall survival *p* = 0.410, recurrence-free survival *p* = 0.405).Fig. 2**a** Recurrence-free survival for TILs in the TCA. TIL^−^ refers to the TIL^-^ group. TIL+ refers to the TIL^+^ group. **b** Recurrence-free survival for CD68^+^ TAMs in the TIF. CD68^+^ TAM^−^ refers to the CD68^−^ group. CD68^+^ TAM^+^ refers to the CD68^+^ group.

Discussion {#Sec13}
==========

In the present work, we determined the level of abundance of monocytes/macrophages and TILs in tumour specimens of patients with de novo HCC in non-cirrhosis after oncologic resection. In addition, their association with patient' clinicopathologic characteristics and survival was analysed. The major discoveries were (1) CD68^+^ TAMs were associated with decreased rates of recurrent and multifocal disease; (2) conversely, M2-polarized TAMs correlated with lymphangiosis carcinomatosa and multifocal HCC; (3) TILs and infiltrating CD68^+^ TAMs were strongly associated in HCC; and (4) had a potent influence on recurrence-free survival.

In this study, we demonstrated that CD68^+^ TAMs and M2-polarized TAMs correlate with established clinicopathologic features of advanced de novo HCC in non-cirrhosis. Of note, 29/58 (50%) of the HCC patients in our study had T3/T4 tumours and 47/58 (81%) tumours exhibited moderate/poor histologic differentiation. These results are in accordance with previously published results in HCC and other hepatobiliary tumours, which report on a negative impact of M2 polarization state of infiltrating TAMs on patient survival and outcome \[[@CR18], [@CR19]\]. However, when considering CD68^+^ TAMs, most published results demonstrate a negative value in regard to patient outcome \[[@CR20]\]. Here, CD68^+^ TAMs were associated with significantly prolonged survival. A possible scenario for our results could be that TAMs comprise a diverse and heterogeneous cell population which can express markers typical not only for M1 or M2 polarization states. Their functionality strongly depends on the signals deployed by the tumour microenvironment, i.e. TAMs re-education and reprogramming as classical tumour escape mechanisms. In line with this, Li et al. demonstrated CD68^+^ TAMs to be also CD204^+^ or CD169^+^ cells. The tissue frequency of CD204^+^ TAMs associated with poor outcome. Conversely, CD169^+^ TAMs were associated with better survival \[[@CR19]\]. Insofar, additional research is needed to investigate the mechanistic interplay between diverse TAMs subpopulations and the tumour microenvironment.

The predominant immune cell population in the tumour vicinity consists mainly of TILs. Accumulating scientific data demonstrates that the type, density and localization of host immunologic tumour infiltration influence its malignant behaviour and could provide clinically informative prognostic biomarkers \[[@CR21]--[@CR23]\]. Furthermore, this immunologic reaction could characterize patient outcome to a greater extent than the diagnostics for the staging of cancer, which are currently applied by conventional histopathology \[[@CR24]\]. Consequently, TILs were identified as a reliable immunologic tool in the tumour microenvironment that could be used in clinical trials and translational research. Insofar, here we focused on the prognostic capacity of TILs in tumour specimens of HCC. Our findings indicate that the presence of TILs significantly influence survival of HCC patients after curative surgery. Of note, in our work, intratumoural prevalence of TILs in liver cancer was correlated with a high frequency of invading TAMs. Thus, it appears possible that infiltrating hepatic monocytes/macrophages and TILs comprise a coherent immunological construct that exerts a significant impact in the process of hepatocarcinogenesis.

In our work, in the setting of oncologic HCC resection, TILs and CD68+ TAMs were associated with better survival rates, which is in line with most published data about TILs' importance in solid cancer that delineates their presence or high tumour density to be associated with improved patient survival \[[@CR17], [@CR25]--[@CR27]\]. Insofar, in this study, we suggest TILs and CD68^+^ TAMs to be reliable cancer biomarkers prognosticating survival and outcome of HCC patients after surgery. However, a possible limitation of the current work is the descriptive nature of our results and the small number of HCC patients with de novo HCC in non-cirrhosis.

Conclusions {#Sec14}
===========

Our study demonstrates that TILs, infiltrating monocytes/macrophages and their functional polarization state associate with multiple tumour characteristics and patient survival in HCC. However, there is only scarce data about the biology underlying mechanistic involvement of TILs, monocytes/macrophages and their polarization in M1 or M2 subtypes in human tumour progression. Thus, a further examination of underlying functional mechanisms that might help develop novel immunologic checkpoint inhibitor targets for liver cancer is warranted.
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